Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.76 USD | -0.17% | +11.41% | -35.93% |
Financials (USD)
Sales 2024 * | 227M | Sales 2025 * | 282M | Capitalization | 823M |
---|---|---|---|---|---|
Net income 2024 * | 9M | Net income 2025 * | 71M | EV / Sales 2024 * | 1.88 x |
Net cash position 2024 * | 395M | Net cash position 2025 * | 448M | EV / Sales 2025 * | 1.33 x |
P/E ratio 2024 * |
99.5
x | P/E ratio 2025 * |
12.2
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.47% |
Latest transcript on Aurinia Pharmaceuticals Inc.
1 day | -1.04% | ||
1 week | +11.32% | ||
Current month | +13.06% | ||
1 month | +15.10% | ||
3 months | -1.62% | ||
6 months | -29.47% | ||
Current year | -35.98% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | -.--% | - | |
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 5.76 | -0.17% | 2 332 517 |
24-05-16 | 5.77 | +8.66% | 2,745,332 |
24-05-15 | 5.31 | +2.12% | 1,761,013 |
24-05-14 | 5.2 | +3.59% | 1,444,777 |
24-05-13 | 5.02 | 0.00% | 845,787 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.98% | 823M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.44% | 22.28B | |
-5.61% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- AUPH Stock